JP2012521191A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521191A5
JP2012521191A5 JP2011551173A JP2011551173A JP2012521191A5 JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5 JP 2011551173 A JP2011551173 A JP 2011551173A JP 2011551173 A JP2011551173 A JP 2011551173A JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence provided
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011551173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521191A (ja
JP5782385B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/024377 external-priority patent/WO2010096418A2/en
Publication of JP2012521191A publication Critical patent/JP2012521191A/ja
Publication of JP2012521191A5 publication Critical patent/JP2012521191A5/ja
Application granted granted Critical
Publication of JP5782385B2 publication Critical patent/JP5782385B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011551173A 2009-02-17 2010-02-17 ヒトox40に対する特異性を有する抗体分子 Expired - Fee Related JP5782385B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15303809P 2009-02-17 2009-02-17
US61/153,038 2009-02-17
PCT/US2010/024377 WO2010096418A2 (en) 2009-02-17 2010-02-17 Antibody molecules having specificity for human ox40

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015063849A Division JP2015171362A (ja) 2009-02-17 2015-03-26 ヒトox40に対する特異性を有する抗体分子

Publications (3)

Publication Number Publication Date
JP2012521191A JP2012521191A (ja) 2012-09-13
JP2012521191A5 true JP2012521191A5 (https=) 2014-04-17
JP5782385B2 JP5782385B2 (ja) 2015-09-24

Family

ID=42634416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011551173A Expired - Fee Related JP5782385B2 (ja) 2009-02-17 2010-02-17 ヒトox40に対する特異性を有する抗体分子
JP2015063849A Pending JP2015171362A (ja) 2009-02-17 2015-03-26 ヒトox40に対する特異性を有する抗体分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015063849A Pending JP2015171362A (ja) 2009-02-17 2015-03-26 ヒトox40に対する特異性を有する抗体分子

Country Status (34)

Country Link
US (3) US8614295B2 (https=)
EP (1) EP2398498B1 (https=)
JP (2) JP5782385B2 (https=)
KR (1) KR101761929B1 (https=)
CN (1) CN102741287B (https=)
AR (1) AR075504A1 (https=)
AU (1) AU2010216152B2 (https=)
BR (1) BRPI1008692B8 (https=)
CA (1) CA2751477C (https=)
CL (1) CL2011001994A1 (https=)
CO (1) CO6410312A2 (https=)
CY (1) CY1121431T1 (https=)
DK (1) DK2398498T3 (https=)
EA (1) EA037792B1 (https=)
ES (1) ES2699716T3 (https=)
HR (1) HRP20181932T1 (https=)
HU (1) HUE042114T2 (https=)
IL (1) IL214282A (https=)
LT (1) LT2398498T (https=)
MA (1) MA33122B1 (https=)
MX (1) MX2011008697A (https=)
MY (1) MY157473A (https=)
NZ (1) NZ594315A (https=)
PE (1) PE20120211A1 (https=)
PL (1) PL2398498T3 (https=)
PT (1) PT2398498T (https=)
SG (3) SG173620A1 (https=)
SI (1) SI2398498T1 (https=)
TN (1) TN2011000374A1 (https=)
TW (1) TWI476281B (https=)
UA (1) UA107341C2 (https=)
UY (1) UY32451A (https=)
WO (1) WO2010096418A2 (https=)
ZA (1) ZA201105500B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614295B2 (en) * 2009-02-17 2013-12-24 Ucb Pharma S.A. Antibody molecules having specificity for human OX40
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
SMT201700185T1 (it) 2010-08-23 2017-05-08 Univ Texas Anticorpi anti-ox40 e metodi di uso degli stessi
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
AP2014007415A0 (en) * 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
CA2845810C (en) * 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AU2012335496B2 (en) 2011-11-11 2017-05-11 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
SMT201800503T1 (it) 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015228372B2 (en) * 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
EP3322443A1 (en) * 2015-07-13 2018-05-23 Yeda Research and Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR101819135B1 (ko) * 2014-03-18 2018-01-18 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗-ox40抗體及其用途
EP3623386B1 (en) * 2015-01-08 2022-04-13 BioNTech SE Agonistic tnf receptor binding agents
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
WO2017063162A1 (zh) * 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
WO2017123673A2 (en) 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体,抗pvrig抗体及其组合
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN110799213A (zh) 2017-06-01 2020-02-14 康姆普根有限公司 三联组合抗体疗法
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
WO2019173780A2 (en) * 2018-03-08 2019-09-12 Magenta Therapeutics, Inc. Anti-cd252 antibodies, conjugates, and methods of use
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
AR114552A1 (es) 2018-08-13 2020-09-16 Inhibrx Inc Polipéptidos de unión a ox40 y sus usos
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
EP3766481A1 (en) * 2019-07-19 2021-01-20 Ichnos Sciences SA Liquid antibody formulation
MX2022007712A (es) 2019-12-17 2022-09-26 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20250339522A1 (en) 2021-10-15 2025-11-06 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
US20250249278A1 (en) 2022-04-14 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US12195546B2 (en) * 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
TW202523691A (zh) * 2023-10-06 2025-06-16 瑞士商伊克諾斯科學公司 親和力成熟之抗-ox40抗體及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2002365814A1 (en) 2001-12-18 2003-07-30 J And J Research Pty Ltd Method of treating asthma
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2528903C (en) * 2004-12-20 2008-01-15 Honda Motor Co., Ltd. Braking device for motorcycle
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
EP2010207A4 (en) 2006-03-22 2009-12-02 Imp Innovations Ltd COMPOSITIONS AND METHODS RELATING TO THE MODULATION OF COMPONENTS OF THE IMMUNE SYSTEM
WO2007112054A2 (en) 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
DK2851374T3 (en) 2007-12-14 2017-06-19 Bristol Myers Squibb Co Binding molecules to the human OX40 receptor
US8614295B2 (en) 2009-02-17 2013-12-24 Ucb Pharma S.A. Antibody molecules having specificity for human OX40
US20120283415A1 (en) * 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
AP2014007415A0 (en) * 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини

Similar Documents

Publication Publication Date Title
JP2012521191A5 (https=)
US12428497B2 (en) Multispecific antibody constructs
RU2018146158A (ru) Антитела
JP2009225799A5 (https=)
JP2018526981A5 (https=)
HRP20191219T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40
JP2011527902A5 (https=)
JP2011504501A5 (https=)
JP2012501670A5 (https=)
JP2017533694A5 (https=)
JP2019515646A5 (https=)
JP2013545455A5 (https=)
JP2012501669A5 (https=)
JP2015519375A5 (https=)
JP2013519364A5 (https=)
JP2010501164A5 (https=)
JP2014529610A5 (https=)
JP2015517492A5 (https=)
JP2019505565A5 (https=)
JP2018508218A5 (https=)
JP2016006052A5 (https=)
JP7689125B2 (ja) ヒトil-13及びil-17に対する結合特異性を有する多重特異性抗体
CN114829398B (zh) 对人il-13具有结合特异性的抗体
CA3164234A1 (en) Multi-specific antibodies
RU2018126315A (ru) Молекулы антител, которые связываются с tnf-альфа